Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa
- 9 May 2018
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 24 (4) , 536-547
Abstract
Aims: To systematically review the effectiveness of on‐demand treatment with recombinant coagulation factor VIIa (rFVIIa) in congenital haemophilia with inhibitors and, if feasible, perform a meta‐analysis of the data.Materials and methods: Publications from Embase®, MEDLINE®, MEDLINE® In‐Process and the Cochrane Central Register of Controlled Trials were searched. Selected publications were reviewed for inclusion by two independent expert reviewers. Discrepancies were reconciled by a third independent reviewer. Data from selected studies were extracted using a predefined grid to ensure uniform and comparable results were captured.Results: A systematic search (cut‐off date of 2 May 2016) identified 20 studies (13 observational; seven randomized controlled trials). All studies were of sufficient quality to include in this analysis and comprised 1221 participants, with 5981 bleeds in 746 individuals treated with rFVIIa. Haemostatic overall effectiveness of the individual studies identified ranged from 68% to 100% at ≤12 hours, 86% to 96% at 13‐24 hours and 76% to 99% at 24‐48 hours with rFVIIa <100 μg/kg, with similar rates reported for the ≥250 μg/kg dose. However, heterogeneity between the studies precluded pooling of results.Conclusions: Data from the individual studies confirmed that rFVIIa is an effective therapy for the on‐demand treatment of bleeds in congenital haemophilia with inhibitors. However, the high levels of heterogeneity between studies precluded pooling of results for a valid, reliable or precise summary measure. There remains a need to implement standardized clinical definitions and measurements for the effectiveness and safety of haemophilia therapies in future clinical trials.Keywords
Funding Information
- Bayer
- Shire
- Novo Nordisk
- Genentech
This publication has 39 references indexed in Scilit:
- Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patientsHaemophilia, 2013
- Results of the WIRK prospective, non‐interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disordersHaemophilia, 2013
- Guidelines for the management of hemophiliaHaemophilia, 2012
- THE EFFECT OF ENGLISH-LANGUAGE RESTRICTION ON SYSTEMATIC REVIEW-BASED META-ANALYSES: A SYSTEMATIC REVIEW OF EMPIRICAL STUDIESInternational Journal of Technology Assessment in Health Care, 2012
- Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trialJournal of Thrombosis and Haemostasis, 2012
- Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparisonHaemophilia, 2007
- A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitorsJournal of Thrombosis and Haemostasis, 2006
- Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitorsThrombosis and Haemostasis, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002